Cargando…

Fecal calprotectin in predicting small bowel capsule endoscopy findings in pediatric patients with known Crohn’s disease

Fecal calprotectin (FC) has been proposed as a noninvasive surrogate marker of intestinal inflammation in inflammatory bowel disease. This study aimed to assess the capability of FC in predicting small bowel capsule endoscopy (SBCE) findings in pediatric patients with known Crohn’s disease (CD). We...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shengnan, Miao, Shijian, Qiu, Xiaoxia, Wu, Jie, Wang, Yuhuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592269/
https://www.ncbi.nlm.nih.gov/pubmed/36281159
http://dx.doi.org/10.1097/MD.0000000000031163
_version_ 1784814886365167616
author Wang, Shengnan
Miao, Shijian
Qiu, Xiaoxia
Wu, Jie
Wang, Yuhuan
author_facet Wang, Shengnan
Miao, Shijian
Qiu, Xiaoxia
Wu, Jie
Wang, Yuhuan
author_sort Wang, Shengnan
collection PubMed
description Fecal calprotectin (FC) has been proposed as a noninvasive surrogate marker of intestinal inflammation in inflammatory bowel disease. This study aimed to assess the capability of FC in predicting small bowel capsule endoscopy (SBCE) findings in pediatric patients with known Crohn’s disease (CD). We retrieved data of consecutive patients aged 2 to 17 years old with established CD who underwent SBCE from Janurary 2017 to April 2020 and had endoscopic remission on ileocolonoscopy. Sixty-eight patients were included in the analysis. There were 13 patients with a weighted pediatric CD activity index ≥ 12.5, 47 patients with FC ≥ 200 µg/g, and 45 patients with significant small bowel (SB) inflammation [Lewis score (LS) ≥ 135]. The LS correlated weakly with FC (R = 0.30, P < .05). The area under the curve of FC as a surrogate diagnostic test for LS ≥ 135 was 0.691, and the optimal FC cutoff values were 242 µg/g with the corresponding sensitivity and specificity of 78% and 65%, respectively. The area under the curve of FC for moderate-to-severe inflammatory activity in the SB was 0.718. In patients with FC level ≥ 670 µg/g, LS ≥ 790 was found in 33% (9/27) of patients, with the sensitivity and specificity of 69% and 67%, respectively. FC may be used to predict SB mucosal inflammation in pediatric patients with confirmed CD having endoscopic remission on ileocolonoscopy.
format Online
Article
Text
id pubmed-9592269
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-95922692022-10-25 Fecal calprotectin in predicting small bowel capsule endoscopy findings in pediatric patients with known Crohn’s disease Wang, Shengnan Miao, Shijian Qiu, Xiaoxia Wu, Jie Wang, Yuhuan Medicine (Baltimore) Research Article Fecal calprotectin (FC) has been proposed as a noninvasive surrogate marker of intestinal inflammation in inflammatory bowel disease. This study aimed to assess the capability of FC in predicting small bowel capsule endoscopy (SBCE) findings in pediatric patients with known Crohn’s disease (CD). We retrieved data of consecutive patients aged 2 to 17 years old with established CD who underwent SBCE from Janurary 2017 to April 2020 and had endoscopic remission on ileocolonoscopy. Sixty-eight patients were included in the analysis. There were 13 patients with a weighted pediatric CD activity index ≥ 12.5, 47 patients with FC ≥ 200 µg/g, and 45 patients with significant small bowel (SB) inflammation [Lewis score (LS) ≥ 135]. The LS correlated weakly with FC (R = 0.30, P < .05). The area under the curve of FC as a surrogate diagnostic test for LS ≥ 135 was 0.691, and the optimal FC cutoff values were 242 µg/g with the corresponding sensitivity and specificity of 78% and 65%, respectively. The area under the curve of FC for moderate-to-severe inflammatory activity in the SB was 0.718. In patients with FC level ≥ 670 µg/g, LS ≥ 790 was found in 33% (9/27) of patients, with the sensitivity and specificity of 69% and 67%, respectively. FC may be used to predict SB mucosal inflammation in pediatric patients with confirmed CD having endoscopic remission on ileocolonoscopy. Lippincott Williams & Wilkins 2022-10-21 /pmc/articles/PMC9592269/ /pubmed/36281159 http://dx.doi.org/10.1097/MD.0000000000031163 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle Research Article
Wang, Shengnan
Miao, Shijian
Qiu, Xiaoxia
Wu, Jie
Wang, Yuhuan
Fecal calprotectin in predicting small bowel capsule endoscopy findings in pediatric patients with known Crohn’s disease
title Fecal calprotectin in predicting small bowel capsule endoscopy findings in pediatric patients with known Crohn’s disease
title_full Fecal calprotectin in predicting small bowel capsule endoscopy findings in pediatric patients with known Crohn’s disease
title_fullStr Fecal calprotectin in predicting small bowel capsule endoscopy findings in pediatric patients with known Crohn’s disease
title_full_unstemmed Fecal calprotectin in predicting small bowel capsule endoscopy findings in pediatric patients with known Crohn’s disease
title_short Fecal calprotectin in predicting small bowel capsule endoscopy findings in pediatric patients with known Crohn’s disease
title_sort fecal calprotectin in predicting small bowel capsule endoscopy findings in pediatric patients with known crohn’s disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592269/
https://www.ncbi.nlm.nih.gov/pubmed/36281159
http://dx.doi.org/10.1097/MD.0000000000031163
work_keys_str_mv AT wangshengnan fecalcalprotectininpredictingsmallbowelcapsuleendoscopyfindingsinpediatricpatientswithknowncrohnsdisease
AT miaoshijian fecalcalprotectininpredictingsmallbowelcapsuleendoscopyfindingsinpediatricpatientswithknowncrohnsdisease
AT qiuxiaoxia fecalcalprotectininpredictingsmallbowelcapsuleendoscopyfindingsinpediatricpatientswithknowncrohnsdisease
AT wujie fecalcalprotectininpredictingsmallbowelcapsuleendoscopyfindingsinpediatricpatientswithknowncrohnsdisease
AT wangyuhuan fecalcalprotectininpredictingsmallbowelcapsuleendoscopyfindingsinpediatricpatientswithknowncrohnsdisease